LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

Inicio・Lista de Acciones・Sanofi

Sanofi

Abierto

57.54 0.7

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

57.01

Máximo

57.14

Métricas clave
By Trading Economics
Ingresos	-20M 1.1B
Ventas	262M 11B
P/B Media del Sector	25.1 103.001
BPA	0.455
Margen de beneficio	9.78
EBITDA	-136M 2B

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 meses	+8.52 upside

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	142B
Apertura anterior	56.84
Cierre anterior	57.54

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

56.26 / 58.24 Soporte y Resistencia

Sanofi Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

25 jul 2024, 05:44 UTC

Ganancias

Sanofi Raises Guidance After Profit, Sales Beat

4 jul 2024, 06:44 UTC

Adquisiciones, fusiones, absorciones

Bain, Cinven Explore Joint Bid for Sanofi's Consumer Unit, Bloomberg Reports

27 jun 2024, 10:54 UTC

Principales Movimientos del Mercado

Vigil Neuroscience Shares Soar on $40 Million Sanofi Investment

26 jun 2024, 07:15 UTC

Adquisiciones, fusiones, absorciones

Sanofi Starts Bidding Process to Sell Consumer Health Division, Bloomberg Reports

13 may 2024, 18:14 UTC

Principales Movimientos del Mercado

Novavax Shares Pop Another 50% Following Sanofi Deal

9 sept 2024, 07:56 UTC

Charlas de Mercado

Big Pharma's Stability in Return on R&D Investment Is Encouraging -- Market Talk

25 jul 2024, 13:20 UTC

Ganancias

AstraZeneca Slides Despite Beating Quarterly Expectations And Hiking Its Outlook -- IBD

25 jul 2024, 11:46 UTC

Charlas de Mercado

Ganancias

Sanofi Aims to Boost RSV Drug Supply -- Market Talk

25 jul 2024, 11:23 UTC

Charlas de Mercado

Ganancias

Sanofi Results Are Positive -- Market Talk

25 jul 2024, 05:33 UTC

Ganancias

Analysts Saw Sanofi 2Q Sales at EUR10.4B

25 jul 2024, 05:33 UTC

Ganancias

Sanofi 2Q Sales EUR10.745B

25 jul 2024, 05:30 UTC

Ganancias

Sanofi Had Seen 2024 Business Earnings Per Share Decreasing Low Single Digit at Constant Currency

25 jul 2024, 05:30 UTC

Ganancias

Sanofi Now Expects 2024 Business Earnings Per Share to Be Stable at Constant Currency

25 jul 2024, 05:30 UTC

Ganancias

Analysts Saw Sanofi 2Q Business Operating Income at EUR2.69B

25 jul 2024, 05:30 UTC

Ganancias

Sanofi 2Q Net Pft EUR1.11B

25 jul 2024, 05:30 UTC

Ganancias

Sanofi Raises 2024 View

25 jul 2024, 05:30 UTC

Ganancias

Sanofi 2Q Business Operating Income EUR2.81B

9 jul 2024, 09:05 UTC

Principales Noticias

These Stocks Are Moving the Most Today: Tesla, Corning, BP, Intel, and More -- Barrons.com

3 jul 2024, 14:18 UTC

Adquisiciones, fusiones, absorciones

GSK Will Pay Up to $1.5 Billion for CureVac's mRNA Vaccines -- Barrons.com

27 jun 2024, 10:39 UTC

Principales Movimientos del Mercado

Vigil Neuroscience Shares Soar on $40M Sanofi Investment

27 jun 2024, 06:08 UTC

Adquisiciones, fusiones, absorciones

Vigil Neuroscience Is a Clinical-Stage Biotechnology Company >VIGL

27 jun 2024, 06:08 UTC

Adquisiciones, fusiones, absorciones

Vigil: Program Includes Clinical Candidate VG-3927, Being Evaluated in Phase 1 Study for Alzheimer's >VIGL

27 jun 2024, 06:08 UTC

Adquisiciones, fusiones, absorciones

Vigil: To Grant Sanofi Exclusive Right of First Negotiation for License of Small Molecule TREM2 Agonist Program >VIGL

27 jun 2024, 06:07 UTC

Adquisiciones, fusiones, absorciones

Vigil Expects Proceeds to Extend Cash Runway Into 2026 >VIGL

27 jun 2024, 06:06 UTC

Adquisiciones, fusiones, absorciones

Vigil: Will Use Proceeds to Fund R&D Activities >VIGL

27 jun 2024, 06:06 UTC

Adquisiciones, fusiones, absorciones

Vigil: Each Share Convertible Into 10 Shares of Common Stock >VIGL

27 jun 2024, 06:06 UTC

Adquisiciones, fusiones, absorciones

Vigil: Sanofi Will Purchase 537,634 of Company's Series A Non-Voting Preferred Shares >VIGL

30 may 2024, 13:10 UTC

Adquisiciones, fusiones, absorciones

Sanofi: Acquisition Relates to Human Protein to Treat Patients With Rare Hereditary Diseases

30 may 2024, 13:08 UTC

Adquisiciones, fusiones, absorciones

Sanofi Completes Acquisition of Biotech Inhibrx

30 may 2024, 13:01 UTC

Adquisiciones, fusiones, absorciones

Press Release: Sanofi Completes Acquisition Of Inhibrx, Inc. >SAN.FR

Comparación entre iguales

Cambio de precio

Sanofi Esperado

Precio Objetivo

By TipRanks

8.52% repunte

Estimación a 12 meses

Media 62 USD 8.52%

Máximo 64 USD

Mínimo 60 USD

De acuerdo con 3 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Sanofi Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

3 ratings

Comprar

Mantener

Vender

De acuerdo con 3 analistas que ofrecen calificaciones bursátiles a para Sanofi Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

56.26 / 58.24Soporte y Resistencia

Recent bearish events outweigh bullish events.

All events are bullish.

Recent bullish events outweigh bearish events.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

EBITDA

Beneficio operativo

Acerca de Sanofi

Sanofi SA is a healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme, among others.